The Role of Mild Thrombocytopenia in mild COVID-19 Infection: A Systematic Review

Abstract—

Introduction:  The COVID-19 pandemic has caused the deaths of more than 9,122,116 people, mostly elderly and/or comorbid such as diabetes and immunosuppressed state using cortisone. While the quarantine measure is necessary, and pancytopenia happens during the hospitalization, earlier thrombocytopenia is often being implemented to manage DHF patients.

Problem: Patients with comorbid have thrombocytopenia and have been managed as DHF patients. Meanwhile, the cost of the pandemic is not limited to medical-aspect, and the virus has led to psychological-aspect of patients not being hospitalized in special COVID-19 barracks.  

Aims: To reveal that thrombocytopenia could be used for COVID-19 diagnosis and as early as possible being managed on COVID-19 treatment management.  

Method: Systematic Review with PRISMA Design, using Science Direct search machine and Mendeley My Library, with keywords thrombocytopenia and mild COVID-19.  Bayesian network and analysis to support in finding references that support the pathogenesis of thrombocytopenia in COVID-19 in the mild stage. Systematic Review and Meta-analysis design are preferable.  

Result: Flowchart of 15 references, supported thrombocytopenia in mild and the severe COVID-19, while lower thrombocytopenia in critical stage.  At least 22 case reports with this mild thrombocytopenia and thrombosis. With over 28,789,321 people infected globally, mild thrombocytopenia in immunocompromised COVID-19 patients could be helped and monitored not to be severe and critical stage as early as possible. 

Conclusion: Mild thrombocytopenia is useful in fighting mortality in the COVID-19 pandemic for primary care physicians.